Advertisement
Canada Markets closed
  • S&P/TSX

    21,837.18
    -11.97 (-0.05%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • DOW

    38,790.43
    +75.66 (+0.20%)
     
  • CAD/USD

    0.7385
    -0.0004 (-0.0524%)
     
  • CRUDE OIL

    82.59
    -0.13 (-0.16%)
     
  • BTC-CAD

    89,200.63
    -2,684.93 (-2.92%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,164.50
    +0.20 (+0.01%)
     
  • RUSSELL 2000

    2,024.74
    -14.59 (-0.72%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • NASDAQ futures

    18,188.25
    -43.25 (-0.24%)
     
  • VOLATILITY

    14.33
    -0.08 (-0.56%)
     
  • FTSE

    7,722.55
    -4.87 (-0.06%)
     
  • NIKKEI 225

    39,596.29
    -144.15 (-0.36%)
     
  • CAD/EUR

    0.6789
    -0.0003 (-0.04%)
     

The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada

For Immediate Release

Chicago, IL – July 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis NVS, Equinix EQIX, Newmont NEM, Enterprise Products Partners EPD and Franco-Nevada FNV.

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for Novartis, Equinix and Newmont Mining

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis, Equinix and Newmont. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

ADVERTISEMENT

You can see all of today’s research reports here >>>

Novartis shares have lagged the Zacks Large-Cap Pharmaceuticals industry over the past year (-3.5% vs. +6.9%), but the Zacks analyst believes that solid performance of key drugs like Cosentyx and Entresto, and contributions from Kisqali and gene therapy, Zolgensma, have improved the company's long-term prospects.

Moreover, the company maintained its annual outlook even amid uncertainties related to the coronavirus pandemic. While the impact of forward purchasing will be reversed as the year progresses, these drugs and new launches like Piqray, Mayzent and Beovu should further boost sales.

The biosimilar portfolio also gains traction with new key approvals. However, price erosion in the United States has adversely impacted the generics business. Moreover, pipeline setbacks and generic competition are concerning.

Shares of Equinix have gained +23.5% over the past six months against the Zacks Retail REIT industry’s fall of -23.3%. The need to work remotely amid the pandemic is driving the demand for interconnected data-center space. The Zacks analyst believes that Equinix, with its interconnectivity-focused global data-center portfolio, is well-positioned to benefit from the tailwind.

Equinix added its 9th IBX data center in the Dallas Infomart Data Center campus in June. The $142-million data center expands its footprint in the Dallas metro area. The company also closed a public offering of four series of senior notes, with $2.6 billion in principal amount.

Also, acceleration in cloud adoption is driving growth for its interconnected ecosystems. Equinix has delivered 69 consecutive quarter revenue growth. Yet, capital-intensive activities amid rising debts are concerning. Also, stiff competition may impact pricing power.

Newmont’s shares have gained +22% over the past three months against the Zacks Mining - Miscellaneous industry’s rise of +30.3%. The Zacks analyst believes that the company is likely to gain from a number of projects including the Tanami expansion, Subika Underground and Ahafo mill expansion.

Moreover, the merger with Goldcorp is expected to be value-accretive to its cash flow and generate significant synergies. Higher gold prices are also expected to continue boosting earnings amid market volatility and economic uncertainties. Newmont is also progressing well on its efficiency improvement programs and remains committed to boost shareholders’ value. However, it faces headwinds from higher production costs.

Expected decline in gold production in the second quarter and 2020 is also likely to hurt the company’s margins. It also faces challenges in the copper market. Lower demand in China and stretched valuation are other concerns.

Other noteworthy reports we are featuring today include Enterprise Products Partners and Franco-Nevada.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                    

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Enterprise Products Partners L.P. (EPD) : Free Stock Analysis Report
 
Equinix, Inc. (EQIX) : Free Stock Analysis Report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
Newmont Corporation (NEM) : Free Stock Analysis Report
 
FrancoNevada Corporation (FNV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research